research Diagnostic criteria for Satoyoshi syndrome
Both azathioprine and betamethasone treatments effectively regrow hair in alopecia areata, but azathioprine may be safer.
Search
for
Sort by
Research
660-690 / 1000+ results research Anifrolumab for systemic lupus erythematosus: A clinical study of Japanese patients in Kanazawa University Hospital
Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.
research Alopecia areata as an immune-related adverse event associated with response to immune checkpoint inhibitors
research S3886 Concurrent Management of Crohn's Ileitis and Alopecia Universalis With Upadacitinib
Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
research TOPICAL IMMUNOTHERAPY IN DERMATOLOGY
Diphencyprone (DCP) is an effective treatment for severe alopecia areata and resistant warts, with some risks.
research A 32‐year‐old woman with arthralgias and severe hypotension
Aggressive immunosuppressive treatment improved a woman's severe heart condition linked to autoimmune disease.
research 710 Use of mass spectrometry imaging and a full thickness 3D skin equivalent for evaluation of percutaneous absorption
The document concludes that various topical treatments show promise for skin conditions like atopic dermatitis, psoriasis, and hair loss.
research A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
research Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report
Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
research FOCAL HYPERTRICHOSIS DURING TOPICAL TACROLIMUS THERAPY FOR CHILDHOOD VITILIGO
An 8-year-old girl with vitiligo developed extra hair growth on her knee after using tacrolimus ointment.
research 27604 Response to baricitinib in the treatment of patients with early and late onset alopecia areata in the phase 2 portion of BRAVE-AA1 randomized controlled trial
Baricitinib was effective in treating both early and late onset alopecia areata.
research Denosumab-induced alopecia areata with lichenoid eruption
Denosumab, a bone loss treatment, may cause hair loss and skin reactions due to immune system effects.
research New Treatment Options for Alopecia Areata
Baricitinib is a new, effective treatment for advanced alopecia areata but is costly and has risks.
research Treatment of severe alopecia areata with baricitinib
Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
research Author reply
Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.
research 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
research Biologics and Small Molecules for Inflammatory Nail Disorders: A Narrative Review
Biologics and small molecules can effectively treat inflammatory nail disorders, but personalized treatment plans are important.
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
research 1434 Epithelially derived MPZL3 negatively regulates murine and human sebaceous gland size and sebocyte proliferation
MPZL3 protein helps control the size of oil glands and the growth of oil-producing cells in both mice and humans.
research Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
research Recalcitrant lichen planopilaris treated with upadacitinib: a case series
Upadacitinib may effectively treat resistant lichen planopilaris.
research Clinical Effectiveness of Two Old Immunosuppressant Drugs, Methotrexate and Azathioprine, in the Treatment of Lichen Planopilaris: A Randomized Clinical Trial
Methotrexate and azathioprine are equally effective and well-tolerated for treating lichen planopilaris.
research Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata
Topical bexarotene 1% gel might help regrow hair in alopecia areata and is generally safe.
research Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839
ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
research AB0987 ANIFROLUMAB TREATMENT IMPROVES QUALITY OF LIFE AND DECREASES SYSTEMIC CORTICOSTEROID USE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Anifrolumab improves quality of life and reduces steroid use in lupus patients.
research JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
research Excessive hair growth around local β‐interferon injection sites for malignant melanoma
β-interferon injections for melanoma can cause excessive hair growth at the injection sites.
research CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
CS12192 effectively treats alopecia areata with better safety than current options.
research A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes
Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
research Anais do II Congresso Nacional Acadêmico de Dermatologia
Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.